Skip to main content

Cosmo Bio Company,Limited (3386.T)

Japan Exchange Group Healthcare Medical - Diagnostics & ResearchView data quality →
55.2Fair

ValueMarkers Composite Index

Top 57%#19,063 of 44,707
Undervalued

55% below intrinsic value ($18)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-2.74
Low Risk
Altman
3.76
Safe
DCF Value
$18
Undervalued
ROIC
2.0%
Low
P/E
21.6
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Cosmo Bio Company,Limited (3386.T) — VMCI valuation read

Cosmo Bio Company,Limited (3386.T) carries a VMCI composite of 55/100, 5 points above the Healthcare sector median of 50. Among mid-cap names, that gap places 3386.T in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 3386.T insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 3386.T trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 2.9x is the rate-sensitivity line to watch, the line to track on Cosmo Bio Company,Limited's next 10-Q.

3386.T fell 1.9% over the trailing 7 days, with a -13.4% read on a 30-day basis.

Cosmo Bio Company,Limited engages in the import, export, manufacture, marketing, and sale of life science research biotools. Its life science research tools include reagents, kits, instruments, software, and diagnostics products. The company offers research reagents, such as antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, bacteria, and others, as well as offers detection reagents, cell and tissue culture systems, gene analysis systems, and others. It also provides research instruments comprising electrophoresis apparatuses, cell culture labware, gene manipulation systems, data analysis software, and others; drug discovery and custom research services; and clinical diagnostics. In addition, the company develops and manufactures cell/cell culture products, including adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, mesenchymal stem, and feeder cells, as well as tumor cell lines, coating reagents, macrophage-related products, etc.; and assay kit related products that comprise various measurement kits, staining kits, detection/purification kits, etc. Further, it offers biotechnology research equipment, which include constant-temperature transport containers, aluminum block mat heat insulation devices, dew condensation prevention glass plates, etc.; and consigned, custom peptide synthesis, and antibody production services. The company serves laboratories, research institutes, and life-science education and testing organizations. It sells its products through outlets in Japan, as well as a network of sales agents internationally. Cosmo Bio Company,Limited was founded in 1978 and is headquartered in Tokyo, Japan.

CEO: Norihiko Shibayama174 employeesJPwww.cosmobio.co.jp

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 3386.T’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.